Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma
Otolaryngology–Head and Neck Surgery · 2023
DOI: 10.1002/ohn.182 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, 2023. Written by David S Lee and 10 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA. Major MEDLINE topics: Carcinoma, Squamous Cell, Oropharyngeal Neoplasms, Papillomavirus Infections, Ototoxicity. Cited 4 times so far (Crossref); 30 references. Funded by: NIDCD NIH HHS.
Abstract (original language)
Objective
To explore whether deintensification of adjuvant therapy reduces ototoxicity among patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC). Study Design Retrospective cohort study.
Setting
Single academic center.
Methods
The ototoxicity rate among adult patients with HPV‐related OPSCC enrolled in the Minimalist Trial (MINT), a prospective phase 2 trial of surgery followed by risk‐adjusted deintensified adjuvant therapy (42 Gy radiation given alone or with a single 100 mg/m 2 dose of cisplatin), was compared to that among a historical cohort treated with standard adjuvant therapy (60‐66 Gy radiation with up to three 100 mg/m 2 doses of cisplatin). Ototoxicity was defined as Common Terminology Criteria for Adverse Events v5.0 ≥ Grade 2. Mixed model analysis was performed to investigate the association between deintensified adjuvant therapy and treatment‐related hearing loss.
Results
A total of 29 patients (58 ears) were analyzed in the MINT cohort, and 27 patients (54 ears) in the historical cohort. The ototoxicity rate was 5% (n = 3/58 ears) in the MINT cohort and 46% (n = 25/54 ears) in the historical cohort (difference, 41%; 95% confidence interval [CI] = 27%‐56%). Patients in the MINT cohort demonstrated a 95% decrease in risk of ototoxicity compared to those in the historical cohort (adjusted odds ratio: 0.05, 95% CI = 0.01‐0.31). Differences in estimated marginal mean threshold shifts were statistically and clinically significant at frequencies ≥ 3 kHz.
Conclusion
The deintensified adjuvant therapy given in MINT led to less ototoxicity than standard adjuvant therapy among patients with HPV‐related OPSCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA.
- Department of Otolaryngology-Head and Neck Surgery, Division of Adult Audiology, Washington University School of Medicine, St Louis, Missouri, USA.
- Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
- Department of Medical Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
ORCID profiles: David S Lee, Theresa Tharakan, Peter Oppelt, Jessica Ley, Cameron C Wick
Funding
- NIDCD NIH HHS
Cite
APA
Lee, D. S., Mahal, R. S., Tharakan, T., Cathryn Collopy, Kallogjeri, D., Thorstad, W. L., Adkins, D. R., Oppelt, P., Ley, J., Wick, C. C., & Zevallos, J. (2023). Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.182
Vancouver
Lee DS, Mahal RS, Tharakan T, Cathryn Collopy, Kallogjeri D, Thorstad WL, et al. Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.182
BibTeX
@article{Lee2023,
author = {Lee, David S and Mahal, Rajwant S and Tharakan, Theresa and Cathryn Collopy and Kallogjeri, Dorina and Thorstad, Wade L and Adkins, Douglas R and Oppelt, Peter and Ley, Jessica and Wick, Cameron C and Zevallos, Jose},
title = {Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
doi = {10.1002/ohn.182}
}
EUVIMED